Promising combo aims to add months for deadly thyroid cancer patients
NCT ID NCT07470489
First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times
Summary
This study tests whether a combination of two drugs, zanzalintinib and cemiplimab, can help people with a rare and fast-growing thyroid cancer called anaplastic thyroid cancer live longer. The goal is to extend average survival by about 4 months. The trial will include 12 adults whose cancer has a specific genetic feature (BRAF wild-type) and who are well enough to be up and about. Participants will receive the drug combination and be monitored for side effects and survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug combo takes aim at deadly thyroid cancer
- Immunotherapy added to standard drugs may fight aggressive thyroid cancer
- New drug combo shows promise against deadly thyroid cancer
- Urine test may spot hidden thyroid cancer, avoid unnecessary surgery
- New hope for advanced thyroid cancer: personalized drug cocktails tested
- New pill shows promise for Hard-to-Treat cancers in early trial